CF
IOVA icon

Corebridge Financial’s Iovance Biotherapeutics IOVA Stock Holding History

Corebridge Financial’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-134,535
Closed -$448K – 1351
2025
Q1 		$448K Sell
134,535
-1,995
-1% -$10.3K ﹤0.01% 1660
2024
Q4 		$1.01M Buy
136,530
+1,151
+0.9% +$10.7K 0.01% 1319
2024
Q3 		$1.27M Sell
135,379
-834
-0.6% -$7.9K 0.01% 1246
2024
Q2 		$1.09M Buy
+136,213
New +$1.46M 0.01% 1285

Other funds holding IOVA

MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Corebridge Financial's IOVA Position: Q2 2025 in Review

Corebridge Financial sold out of Iovance Biotherapeutics (IOVA) in Q2 2025, closing a stake of 134,535 shares — an estimated $448K sold.

Corebridge Financial first reported a position in IOVA in Q2 2024 and held it in 4 quarters. The position peaked at $1.27M in Q3 2024. 254 funds tracked by Wall St. Rank hold IOVA as of Q2 2025.

  • Corebridge Financial reported no remaining Iovance Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 134,535 Iovance Biotherapeutics shares in Q2 2025, an estimated $448K.
  • Corebridge Financial first reported a position in Iovance Biotherapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Iovance Biotherapeutics position peaked at $1.27M in Q3 2024.
  • 254 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.